Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/01/2026 ,inter alia, to consider and approve Un-audited Standalone ....
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals has informed BSE and NSE that its Board of Directors will meet on Tuesday, January 20, 2026. The key agenda is to consider and approve the Un-audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025 (Q3FY26 and 9MFY26). The company also referenced its earlier intimation from December 25, 2025, regarding the closure of the trading window for insiders from January 1, 2026, until 48 hours after the results are filed with the stock exchanges. No financial figures or business details have been disclosed in this filing.
This is a standard pre-results intimation with no direct impact on the stock. Investors should watch for the Q3FY26 results on January 20, 2026, which could move the stock depending on the numbers reported. The closed trading window signals that insiders are restricted from trading until the results are out.